title: Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer.
abstract: Continuous hyperthermic peritoneal perfusion (CHPP) with a solution which contains 30 mg mitomycin C and 300 mg cisplatin has been introduced as a prophylactic treatment for peritoneal recurrence after curative resection of 79 advanced gastric cancers. The control group consisted of 81 patients with advanced gastric cancer who underwent curative surgery during the same period. CHPP was performed for 60 minutes by perfusing MMC- and CDDP-containing saline solutions warmed at 43.5 degrees C by a special CHPP device. In patients with pathologically confirmed serosal invasion-positive tumors, the survival rate of the CHPP group was significantly higher than that of the control group. A survival advantage for stage IV patients was also obtained by CHPP. However, there was no survival advantage between the CHPP group and the control group with serosal invasion-negative tumors. Adverse effects were observed in four patients who underwent CHPP: One developed severe bone marrow suppression, and transient hyperazotemia was observed in the other three. There was no difference in the incidence of mortality and morbidity between the two groups. These results indicate that CHPP is a safe, readily available prophylactic therapy for peritoneal recurrence after gastric cancer surgery.
authors.affiliation: Second Department of Surgery, School of Medicine, Kanazawa University, Ishikawa, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Yonemura
authors.forename: I
authors.initials: I
authors.lastname: Ninomiya
authors.forename: M
authors.initials: M
authors.lastname: Kaji
authors.forename: K
authors.initials: K
authors.lastname: Sugiyama
authors.forename: K
authors.initials: K
authors.lastname: Fujimura
authors.forename: T
authors.initials: T
authors.lastname: Sawa
authors.forename: K
authors.initials: K
authors.lastname: Katayama
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Hirono
authors.forename: K
authors.initials: K
authors.lastname: Miwa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D005743:Gastrectomy; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D010477:Perfusion; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000517:prevention & control* / Q000556:secondary; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
chemical_list: D016685:Mitomycin; D002945:Cisplatin